Home › Forums › Other Specialities › Therapeutics › (vedolizumab)- FDA approval- treatment of Active UC, Crohns
- This topic has 0 replies, 1 voice, and was last updated 1 year, 1 month ago by
Anonymous.
-
AuthorPosts
-
-
December 21, 2023 at 1:45 pm #2792
Anonymous
InactiveFDA Approves Takeda’s Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease.
“Entyvio is a new option that works to block important contributors to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn’s disease,” said Stephen B. Hanauer, M.D., medical director, Digestive Health Center, Northwestern UniversityFeinberg School of Medicine. “The clinical trial program evaluated the efficacy and safety profile of Entyvio and demonstrated that Entyvio has the potential to help adult patients with moderately to severely active UC or CD successfully manage their disease.”
Entyvio is now approved for inducing and maintaining clinical response and remission, improving endoscopic appearance of the mucosa, and achieving corticosteroid-free remission in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
“Patients with moderately to severely active ulcerative colitis or Crohn’s disease, and the healthcare professionals who care for them, need additional new treatment options,” said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. “Entyvio reflects an expansion of Takeda’s commitment to supporting patients with gastrointestinal disorders.”
The Entyvio dose regimen is 300 mg infused intravenously over approximately 30 minutes at zero, two and six weeks, then every eight weeks thereafter. Patients should be observed during infusion and until the infusion is complete.
In March, Entyvio received a positive Opinion for the treatment of adults with moderately to severely active UC and CD from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and Takeda is awaiting response from the European Commission on approval for Marketing Authorisation.
Request Drug Profile ,if needed.
G Mohan.
-
-
AuthorPosts
- You must be logged in to reply to this topic.